Futura Medical PLC
LSE:FUM

Watchlist Manager
Futura Medical PLC Logo
Futura Medical PLC
LSE:FUM
Watchlist
Price: 1.225 GBX -0.41%
Market Cap: 7.1m GBX

Futura Medical PLC
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Futura Medical PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Futura Medical PLC
LSE:FUM
Revenue
ÂŁ7.9m
CAGR 3-Years
N/A
CAGR 5-Years
202%
CAGR 10-Years
63%
GlaxoSmithKline PLC
LSE:GSK
Revenue
ÂŁ32.2B
CAGR 3-Years
3%
CAGR 5-Years
-1%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Revenue
$58.1B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
9%
Verona Pharma PLC
NASDAQ:VRNA
Revenue
$221.7m
CAGR 3-Years
77%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Revenue
$1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Revenue
$3.2B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
8%
No Stocks Found

Futura Medical PLC
Glance View

Market Cap
7.1m GBX
Industry
Pharmaceuticals

Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

FUM Intrinsic Value
9.197 GBX
Undervaluation 87%
Intrinsic Value
Price

See Also

What is Futura Medical PLC's Revenue?
Revenue
7.9m GBP

Based on the financial report for Jun 30, 2025, Futura Medical PLC's Revenue amounts to 7.9m GBP.

What is Futura Medical PLC's Revenue growth rate?
Revenue CAGR 10Y
63%

Over the last year, the Revenue growth was -6%.

Back to Top